57 Intermittent amifostine reduces acute toxicity during postoperative chemoradiation of rectal cancer

Semlin, S.; Reese, Thomas J.; Sutter, Thomas R.; Dunst, Jürgen

doi:10.1016/s0360-3016(99)90075-5

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to radiation, several approaches are under study to enhance its effect on tumor volume or minimize toxicity, including altered fractionation regimens using delayed concomitant boost radiotherapy [119] or accelerated hyperfractionation [120], conformal therapy [121], and radioprotectants such as amifostine [122]. Intraoperative radiation, currently used primarily for initially unresectable or recurrent rectal cancers [123], has been explored for high-risk T3 cancers [124].…”

Section: New Adjuvant Regimensmentioning

confidence: 99%

Adjuvant therapy for resectable rectal adenocarcinoma

Harrison

2000

Seminars in Surgical Oncology

View full text Add to dashboard Cite

The mainstay of treatment for rectal cancer over the past 100 years has been surgical resection. However, for the majority of rectal cancers treated conventionally by resection alone, locoregional recurrence is the major mode of failure. Over the past several decades, significant progress has been made in developing effective adjuvant regimens. In the United States, postoperative chemoradiation is standard treatment for T3 or node-positive patients. However, preoperative radiation with or without chemotherapy decreases local recurrence, increases sphincter preservation, and may improve survival. The purpose of this article is to review the role of adjuvant therapy in resectable rectal cancers and to update the status of ongoing randomized trials.

show abstract